娄艳茹

临床药学与药事管理学, 研究员, 博士生导师



姓名
娄艳茹
性别
女

职称
研究员
学历
博士

电话
**
传真


电子邮件
yanru_lou@fudan.edu.cn
个人主页


通讯地址
上海市浦东新区张衡路826号科研楼东辅楼205



教育经历
1999.08 - 2005.12芬兰坦佩雷大学，医学院解剖学系，博士
1992.09 - 1996.06华西医科大学，药学院药学专业，学士


工作经历
2020.07 - 至今 复旦大学，药学院临床药学与药事管理系，研究员，博士生导师
2016.09 芬兰赫尔辛基大学，药学院生物药剂学副教授
2015.09 - 2016.12芬兰科学院，科学院研究员
2014.09 - 2014.12美国北卡罗来纳大学教堂山分校，医学院，访问****
2013.09 - 2013.10美国新墨西哥大学，化学与生物分子工程系，访问****
2011.07 - 2019.05芬兰赫尔辛基大学，药学院药物生物科学系，大学研究员
2009.12 - 2019.05芬兰赫尔辛基大学，药学院，PI
2009.07 - 2011.06芬兰赫尔辛基大学，药学院生物药剂与药代动力学系，博士后
2007.09 - 2009.07新加坡A*STAR生物工程与纳米技术研究院，研究科学家
2006.09 - 2007.08芬兰坦佩雷大学，REGEA再生医学研究所，资深研究员
2005.12 - 2006.08芬兰坦佩雷大学，医学院解剖学系，博士后
1996.07 - 1999.06西安市药品检验所，药师


承担科研项目情况
2019.01 - 2019.09芬兰国家教育局13500 欧元 主持2018.05 - 2019.12芬兰赫尔辛基大学8000欧元 主持
2015.09 - 2016.12芬兰赫尔辛基大学40000欧元 主持
2015.09 - 2016.12芬兰科学院260000欧元 主持
2015.07 - 2016.03芬兰国家教育局13500 欧元 主持
2015.03 - 2016.12芬欧汇川330000 欧元 主持
2008.09 - 2010.12芬兰科学院189000欧元 主持
2007.08 - 2012.12芬兰坦佩雷大学医院医学研究基金9400欧元 主持
2006.09 - 2011.12芬兰坦佩雷大学医院医学研究基金10000欧元 主持
2001 - 2005芬兰坦佩雷大学医院医学研究基金21200欧元 主持


获奖及荣誉
2015年荣获芬兰科学院颁发的研究员奖
2008年荣获芬兰科学院颁发的博士后研究员奖
2004年荣获中国国家留学基金管理委员会颁发的国家优秀自费留学生奖
2000 - 2002芬兰坦佩雷生物医学与生物技术研究生院研究生奖学金




研究方向
1. 药物代谢2. 干细胞，3D培养和基因组编辑技术
3. 体外药动药效学模型


科研成果

1.建立高效的，用于人多能干细胞的基因组编辑技术。
2. 通过研究肝祖细胞建立新型生物材料用于干细胞的诱导分化。
3. 利用不同类型的3D细胞培养技术诱导分化干细胞并构建类器官。
4. 研发植物衍生的生物材料用于3D细胞培养并商业化。
5. 发现25-羟基维生素D是活性激素。
6. 培养博士生4名，其中3名已获得学位（分别就职于美国哈佛大学、阿斯利康和瑞典卡罗林斯卡学院），目前在读1名。
7. 培养硕士生16名，其中15名获得学位（分别就职于丹麦诺和诺德，芬兰奥立安等公司），目前在读1名。
8. 授权国际发明专利9项，产品1项。

学术兼职
1.2020年8月至今担任SCI期刊《Scientific Reports》Senioreditor (https://www.nature.com/srep/about/editors#senior-editorial-board)
2. 2020年担任爱沙尼亚研究理事会科学基金项目评审专家
3. 2019年担任英国医学研究理事会、英国经济与社会研究理事会和加拿大卫生研究院科学基金项目评审专家
4.2019年担任新加坡国立大学综合科学与工程研究生院博士论文外聘审查员
5. 2017年1月- 2020年7月担任SCI期刊《Scientific Reports》编辑
6. 2016年 - 2018年担任赫尔辛基大学Doctoral Programme in Materials Research and Nanosciences博士论文委员会成员
7. 2016年 - 2017年担任SCI期刊《Stem Cells International》Lead guest editor
8. 2016年担任荷兰卫生研究与发展组织科学基金项目评审专家
9. 2013年担任赫尔辛基大学FinPharma Doctoral Program博士论文中期答辩委员会成员
10. 2006年担任英国国际癌症研究协会科学基金项目评审专家
11. 2004年 - 2020年担任芬兰内分泌学会会员
12. 2004年至今为32个著名国际科学期刊审稿



代表性论著
已发表学术论文46篇，H-index 25，总SCI他引超过2200次, 其中他引超100次的论文8篇。授权发明专利9项，产品1项。ORCID ID: 0000-0001-7717-6010
1. RNA-based CRISPR-mediated loss-of-function mutagenesis in human pluripotent stem cells. Alan W. Leung, Cayla Broton, Mariia S. Bogacheva, Andrew Z. Xiao, Martin I. Garcia-Castro, Yan-Ru Lou*. Journal of Molecular Biology 2020;432(13):3956-3964.
2. AFM force spectroscopy reveals the role of integrins and their activation in cell-biomaterial interactions. Riina Harjum?ki, Xue Zhang, Robertus Wahyu N. Nugroho, Muhammad Farooq, Yan-Ru Lou, Marjo Yliperttula, Juan José Valle-Delgado, Monika ?sterberg. ACS Applied Bio Materials 2020;3(3):1406-1417.
3. Quantified forces between HepG2 hepatocarcinoma and WA07 pluripotent stem cells with natural biomaterials correlate with in vitro cell behavior. Riina Harjum?ki, Robertus Wahyu N. Nugroho, Xue Zhang, Yan-Ru Lou, Marjo Yliperttula, Juan José Valle-Delgado, Monika ?sterberg. Scientific Reports 2019;9:7354.
4. Quantifying the interactions between biomimetic biomaterials - collagen I, collagen IV, laminin 521 and cellulose nanofibrils - by colloidal probe microscopy. Robertus Wahyu N. Nugroho, Riina Harjum?ki, Xue Zhang, Yan-Ru Lou, Marjo Yliperttula, Juan José Valle-Delgado, Monika ?sterberg. Colloids and Surfaces B: Biointerfaces 2019;173:571-580.
5. A feasibility study of the toxic responses of human induced pluripotent stem cell-derived hepatocytes to phytochemicals. Tomá? Smutny, Riina Harjum?ki, Liisa Kanninen, Marjo Yliperttula, Petr Pávek, Yan-Ru Lou*. Toxicology in Vitro 2018;52:94-105.
6. Next generation organoids for biomedical research and applications. Yan-Ru Lou*, Alan W. Leung. Biotechnology Advances 2018;36:132-149.
7. Differences in definitive endoderm induction approaches using growth factors and small molecules. Mariia S. Bogacheva, Sofia Khan, Liisa K. Kanninen, Marjo Yliperttula, Alan W. Leung, Yan-Ru Lou*. Journal of Cellular Physiology 2018;233:3578-3589.
8. Nanofibrillar cellulose-alginate hydrogel coated surgical sutures as cell-carrier systems. Patrick Laurén, Petter Somersalo, Irina Pitk?nen, Yan-Ru Lou, Arto Urtti, Jouni Partanen, Jukka Sepp?l?,, Mari Madetoja, Timo Laaksonen, Antti M?kitie, Marjo Yliperttula. PLoS One 2017;12(8):e**.
9. Multicellular dosimetric chain for molecular radiotherapy exemplified with dose simulations on 3D cell spheroids. Vappu Reijonen, Liisa Kanninen, Eero Hippel?inen, Yan-Ru Lou, Eero Salli, Alexey Sofiev, Melina Malinen, Timo Paasonen, Marjo Yliperttula, Antti Kuronen, Sauli Savolainen. Physica Medica 2017;40:72-78.
10. 25-Hydroxyvitamin D3 induces osteogenic differentiation of human mesenchymal stem cells. Yan-Ru Lou*, Tai Chong Toh, Yee Han Tee, Hanry Yu. Scientific Reports 2017;7:42816.
11. Laminin-511 and laminin-521-based matrices for efficient hepatic specification of human pluripotent stem cells. Liisa Kanninen, Riina Harjum?ki, Pasi Peltoniemi, Mariia Bogacheva, Tuuli Salmi, Pauliina Porola, Johanna Niklander, Tomá? Smutny, Arto Urtti, Marjo Yliperttula, Yan-Ru Lou*. Biomaterials 2016;103:86-100.
12. Feasibility study of the permeability and uptake of mesoporous silica nanoparticles across the blood-brain barrier. Habib Baghirov, Didem Karaman, Tapani Viitala, Alain Duchanoy, Yan-Ru Lou, Veronika Mamaeva, Evgeny Pryazhnikov, Leonard Khiroug, Catharina de Lange Davies, Cecilia Sahlgren, Jessica M. Rosenholm. PLoS ONE 2016;11(8):e**.
13. Hepatic differentiation of human pluripotent stem cells on human liver progenitor HepaRG-derived acellular matrix. Liisa Kanninen, Pauliina Porola, Johanna Niklander, Melina Malinen, Anne Corlu, Christiane Guguen-Guillouzo, Arto Urtti, Marjo Yliperttula, Yan-Ru Lou*. Experimental Cell Research 2016;341(2):207-217.
14. Silica bioreplication preserves three-dimensional spheroid structures of human pluripotent stem cells and HepG2 cells. Yan-Ru Lou*, Liisa Kanninen, Bryan Kaehr, Jason Townson, Johanna Niklander, Riina Harjum?ki, C. Jeffrey Brinker, Marjo Yliperttula. Scientific Reports 2015;5:13635.
15. Effect of cell differentiation on endocytic profiles of endothelial and epithelial cell culture models. Polina Ilina, Susanna Partti, Johanna Niklander, Marika Ruponen, Yan-Ru Lou*, Marjo Yliperttula. Experimental Cell Research 2015;332(1):89-101.
16. Technetium-99m-labeled nanofibrillar cellulose hydrogel for in vivo drug release. Patrick Laurén, Yan-Ru Lou, Mari Raki, Arto Urtti, Kim Berstr?m, Marjo Yliperttula. European Journal of Pharmaceutical Sciences 2014;65:79-88.
17. A critical assessment of in vitro tissue models for ADME and drug delivery. Kati-Sisko Vellonen, Melina Malinen, Eliisa Mannermaa, Astrid Subrizi, Elisa Toropainen, Yan-Ru Lou, Heidi Kidron, Marjo Yliperttula, Arto Urtti. Journal of Controlled Release 2014;190:94-114.
18. Differentiation of liver progenitor cell line to functional organotypic cultures in 3D Nanofibrillar cellulose and hyaluronan-gelatin hydrogels. Melina Malinen, Liisa Kanninen, Anne Corlu, Helena Isoniemi, Yan-Ru Lou, Marjo Yliperttula, Arto Urtti. Biomaterials 2014;35(19):5110-5121.
19. The use of nanofibrillar cellulose hydrogel as a flexible three-dimensional model to culture human pluripotent stem cells. Yan-Ru Lou*, Liisa Kanninen, Tytti Kuisma, Johanna Niklander, Luke Noon, Deborah Burks, Arto Urtti, Marjo Yliperttula. Stem Cells and Development 2014;23(4):380-392. Featured on the journal cover.
20. Gene expression profiles in human and mouse primary cells provide new insights into the differential actions of vitamin D3 metabolites. Pentti Tuohimaa, Jing-Huan Wang, Sofia Khan, Marianne Kuuslahti, Kui Qian, Tommi Manninen, Petri Auvinen, Mauno Vihinen, Yan-Ru Lou*. PLoS One 2013;8(11):e75338.
21. Nanofibrillar cellulose hydrogel promotes three-dimensional liver cell culture. Madhushree Bhattacharya, Melina M Malinen, Patrick Lauren, Yan-Ru Lou, Saara W Kuisma, Liisa Kanninen, Martina Lille, Anne Corlu, Christiane GuGuen-Guillouzo, Olli Ikkala, Antti Laukkanen, Arto Urtti, Marjo Yliperttula. Journal of Controlled Release 2012;164(3):291-298.
22. Optimal serum calcidiol concentration for cancer prevention. Pentti Tuohimaa and Yan-Ru Lou. Anticancer Research 2012;32(1):373-381.
23. Vitamin D3: Is there an upper limit? Pentti Tuohimaa, Marianne Kuuslahti, and Yan-Ru Lou. BMJ-British Medical Journal 2010 All rapid responses. 19 May 2010
24. 25-Hydroxyvitamin D3 is an agonistic vitamin D receptor ligand. Yan-Ru Lou*, Ferdinand Molnár, Mikael Per?kyl?, Shengjun Qiao, Allan V. Kalueff, René St-Arnaud, Carsten Carlberg, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2010;118(3):162-170.
25. Premature aging in vitamin D receptor knockout mice. Tiina Keisala, Anna Minasyan, Yan-Ru Lou, Jing Zou, Allan V. Kalueff, Ilmari Pyykk?, and Pentti, Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2009;115(3-5):91-97.
26. Vestibular dysfunction in vitamin D receptor mutant mice. Anna Minasyan, Tiina Keisala, Jing Zou, Ya Zhang, Esko Toppila, Heimo Syv?l?, Yan-Ru Lou, Allan V. Kalueff, Ilmari, Pyykk?, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2009;114(3-5):161-166.
27. Progressive hearing loss in mice with a mutated vitamin D receptor gene. Jing Zou, Anna Minasyan, Tiina Keisala, Ya Zhang, Jing-Huan Wang, Yan-Ru Lou, Allan Kalueff, Ilmari Pyykk?, and Pentti Tuohimaa. Audiology and Neuro-otology 2008;13(4):219-230.
28. What can we learn from the mutant mice about the possible link between neurosteroid vitamin D and anxiety? Allan V. Kalueff, Anna Minasyan, Yan-Ru Lou, Ilkka Laaksi, and Pentti Tuohimaa. Psychopharmacology and Biological Narcology 2008;5:930-938.
29. Neophobia, sensory and cognitive functions, and hedonic responses in vitamin D receptor mutant mice. Anna Minasyan, Tiina Keisala, Yan-Ru Lou, Allan V. Kalueff, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2007;104(3-5):274-280.
30. Thalamic calcification in vitamin D receptor knockout mice. Allan V. Kalueff, Elena Loseva, Hannu Haapasalo, Immo Rantala, Jaakko Keranen, Yan-Ru Lou, Anna Minasyan, Tiina Keisala, Susanna Miettinen, Marianne Kuuslahti, and Pentti Tuchimaa. Neuroreport 2006;17(7):717-721.
31. Androgen enhances the antiproliferative activity of vitamin D3 by suppressing 24-hydroxylase expression in LNCaP cells. Yan-Ru Lou* and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2006;99(1):44-49.
32. Retinoic acid via RARa inhibits the expression of 24-hydroxylase in human prostate stromal cells. Yan-Ru Lou*, Susanna Miettinen, Hiroyuki Kagechika, Hinrich Gronemeyer, and Pentti Tuohimaa. Biochemical and Biophysical Research Communications 2005;338(4):1973-1981.
33. 5a-Dihydrotestosterone inhibits 1a,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells. Yan-Ru Lou*, Nadja Nazarova, Riikka Talonpoika, and Pentti Tuohimaa. Prostate 2005;63(3):222-230.
34. Regulation of aromatase and 5a-reductase by 25-hydroxyvitamin D3, 1a,25-dihydroxyvitamin D3, dexamethasone and progesterone in prostate cancer cells. Yan-Ru Lou*, Teemu Murtola, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2005;94(1-3):151-157.
35. Calcidiol and prostate cancer. Pentti Tuohimaa, Olga Golovko, Allan V. Kalueff, Nadja Nazarova, Shengjun Qiao, Heimo Syv?l?, Riikka Talonpoika, and Yan-Ru Lou. Journal of Steroid Biochemistry and Molecular Biology 2005;93(2-5):183-190.
36. Abnormal behavioral organization of grooming in mice lacking the vitamin D receptor gene. Allan V. Kalueff, Yan-Ru Lou, Ilkka Laaksi, and Pentti Tuohimaa. Journal of Neurogenetics 2005;19(1):1-24.
37. Calcitriol-induced prostate-derived factor: autocrine control of prostate cancer cell growth. Nadja Nazarova, Shengjun Qiao, Olga Golovko, Yan-Ru Lou, and Pentti Tuohimaa. International Journal of Cancer 2004;112(6):951-958.
38. The role of vitamin D3 metabolism in prostate cancer. Yan-Ru Lou, Shengjun Qiao, Riikka Talonpoika, Heimo Syv?l?, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2004;92(4):317-325.
39. Increased grooming behavior in mice lacking vitamin D receptors. Allan V. Kalueff, Yan-Ru Lou, Ilkka Laaksi, and Pentti Tuohimaa. Physiology & Behavior 2004;82(2-3):405-409.
40. Impaired motor performance in mice lacking neurosteroid vitamin D receptors. Allan V. Kalueff, Yan-Ru Lou, Ilkka Laaksi, and Pentti Tuohimaa. Brain Research Bulletin 2004;64(1):25-29.
41. Increased anxiety in mice lacking vitamin D receptor gene. Allan V. Kalueff, Yan-Ru Lou, Ilkka Laaksi, and Pentti Tuohimaa. Neuroreport 2004;15(8):1271-1274.
42. Role of 24-hydroxylase in vitamin D3 growth response of OVCAR-3 ovarian cancer cells. Susanna Miettinen, Merja H. Ahonen, Yan-Ru Lou, Tommi Manninen, Pentti Tuohimaa, Heimo Syv?l?, and Timo Ylikomi. International Journal of Cancer 2004;108(3):367-373.
43. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. Yan-Ru Lou*, Ilkka Laaksi, Heimo Syv?l?, Merja Bl?uer, Teuvo L.J. Tammela, Timo Ylikomi, and Pentti Tuohimaa. FASEB Journal 2004;18(2):332-334.
44. Inhibition of fatty acid synthase expression by 1a,25-dihydroxyvitamin D3 in prostate cancer cells. Shengjun Qiao, Pasi Pennanen, Nadya Nazarova, Yan-Ru Lou, and Pentti Tuohimaa. Journal of Steroid Biochemistry and Molecular Biology 2003;85(1):1-8.
45. Antiproliferative action of vitamin D. Timo Ylikomi, Ilkka Laaksi, Yan-Ru Lou, Paula Martikainen, Susanna Miettinen, Pasi Pennanen, Sami Purmonen, Heimo Syv?l?, Annika Vienonen, and Pentti Tuohimaa. Vitamins and Hormones 2002;64:357-406.
46. Vitamin D and prostate cancer. Pentti Tuohimaa, Alex Lyakhovich, Nickolai Aksenov, Pasi Pennanen, Heimo Syv?l?, Yan-Ru Lou, Merja Ahonen, T. Hasan, P. Pasanen, Merja Bl?uer, Tommi Manninen, Susanna Miettinen, Pekka Vilja, and Timo Ylikomi. Journal of Steroid Biochemistry and Molecular Biology 2001;76(1-5):125-134.